GenPat77 Pharmacogenetics AG
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GenPat77 Pharmacogenetics AG
CellAct Pharma GMBH is developing drug candidates for cancer and immune-modulated inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and transplant rejection. Its lead compound targets topoisomerases and is in clinical Phase I study for the treatment of cancer. The company is also developing antibodies against surface molecules in lymphocytes to treat inflammation.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.